A PHASEIB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
F. Hoffmann-La Roche Ltd
Start Date
December 5, 2019
End Date
July 1, 2022
Administered By
Duke Cancer Institute
Awarded By
F. Hoffmann-La Roche Ltd
Start Date
December 5, 2019
End Date
July 1, 2022